JieRun and XiRun Launched in China to Enable More COPD Patients to Breathe Freely

Shanghai, April 28, 2019 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) is one of the five major chronic non-communicable diseases listed by the World Health Organization (WHO). In 2018, COPD became the fourth leading cause of death among Chinese residents, and it is projected to rise to the third position by 2020, imposing a significant burden on society. Data shows that nearly 100 million people in China are affected by COPD; however, awareness and diagnosis rates remain far from satisfactory, and there is substantial room for improvement in standardized treatment. In March 2019,Two Globally Leading Innovative Original DrugsJierun®(Indacaterol/Glycopyrronium bromide), Xirun®(Glycopyrronium Bromide)In ChinaDomesticCity,with the marketedOnbrez® (Indacaterol Maleate)Jointly Composed OfThe comprehensive COPD product portfolio can be more precisely applied to the most suitable patient populations with COPD,These three pharmaceutical products are all manufactured by Novartis, with Hanshui Pharmaceutical responsible for their exclusive nationwide promotion in China.

Meanwhile, with the support of numerous experts in the field of respiratory medicine,ByHisun Pharmaceutical SpecialInitiated[Chinese Academy of Acute and Chronic Airway Diseases Management (CAMACAD)]Establishment, aiming to leverage this comprehensive academic platform，Harnessing the expertise of respiratory specialists through collaborative efforts to promote the improvement of standardized diagnosis and treatment throughout the entire course of chronic obstructive pulmonary disease (COPD) in China.

On April 19, the CAMACAD Speaker Training Program was launched, inviting numerous leading experts in the field of respiratory medicine in China to jointly discuss cutting-edge academic advances and hot clinical issues. Professor Chen Rongchang from the First Affiliated Hospital of Guangzhou Medical University and Professor Bai Chunxue from Zhongshan Hospital Fudan University attended the conference as co-chairs. Through this event, CAMACAD speakers further disseminated academic information on COPD treatment via the academy’s integrated platform, bringing effective solutions to the frontline of medical practice in China and enabling more standardized diagnosis and treatment for a greater number of COPD patients.

Experts Point Out：“Bronchodilators remain the cornerstone of COPD treatment; ideal bronchodilation can effectively improve lung function and enhance physical capacity.”Onbrez®, Seebri®, Ultibro®These three bronchodilator products possess distinct clinical advantages and optimal target patient populations, offering broad prospects for clinical application.Among them, Onbrez® has been included in the China National Reimbursement Drug List; the suggested retail price for Xirun® is RMB 415 per box.(Glycopyrronium bromide50 mcg * 30 capsules), average daily treatment costRMB 13.8. The suggested retail price for JieRun® is RMB 620 per box.（Indacaterol110 mcg/glycopyrronium bromide 50 mcg * 30 capsules), average daily treatment cost20.7 yuan, currentlyXirun®, Jierun® Both are actively applying for inclusion in the National Reimbursement Drug List, with the aim of enabling more patients with chronic obstructive pulmonary disease (COPD) to enjoy free and easy breathing.

Mr. Li Yan, President of Hisun Pharmaceutical Group and CEO of Huihui Pharmaceuticals, stated that he sincerely hopes to join forces with leading experts in the medical community through such high-quality, highly compliant academic programs, bringing global leadingAnrun®, Xirun®, Jierun®Three maintenance therapy drugs for chronic obstructive pulmonary disease (COPD) are provided to patients in need at the fastest speed, benefiting more Chinese COPD patients. Hansoh Pharmaceutical possesses a relatively complete portfolio of corticosteroid and anti-infective products, and has accumulated extensive experience in collaborations within the respiratory disease field, supported by a network that combines both depth and breadth.Onbrez®, Xirun®Jie Run®The launch and promotion of three inhalers, in conjunction with the existing product portfolio, will establish a more comprehensive product lineup for the treatment of acute and chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). This will provide greater support to numerous patients, alleviate the suffering caused by these conditions, and thereby contribute positively to improving national public health.